alexa A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection.
Microbiology

Microbiology

Journal of Bacteriology & Parasitology

Author(s): Ritmeijer K, Dejenie A, Assefa Y, Hundie TB, Mesure J,

Abstract Share this page

Abstract BACKGROUND: Antimonials are the mainstay of visceral leishmaniasis (VL) treatment in Africa. The increasing incidence of human immunodeficiency virus (HIV) coinfection requires alternative safe and effective drug regimens. Oral miltefosine has been proven to be safe and effective in the treatment of Indian VL but has not been studied in Africa or in persons with HIV and VL coinfection. METHODS: We compared the efficacy of miltefosine and sodium stibogluconate (SSG) in the treatment of VL in persons in Ethiopia. A total of 580 men with parasitologically and/or serologically confirmed VL were randomized to receive either oral miltefosine (100 mg per day for 28 days) or intramuscular SSG (20 mg/kg per day for 30 days). RESULTS: The initial cure rate was 88\% in both treatment groups. Mortality during treatment was 2\% in the miltefosine group, compared with 10\% in the SSG group. Initial treatment failure was 8\% in the miltefosine group, compared with 1\% in the SSG group. Among the 375 patients (65\%) who agreed to HIV testing, HIV seroprevalence was 29\%. Among patients not infected with HIV, initial cure, mortality, and initial treatment failure rates were not significantly different (94\% vs. 95\%, 1\% vs. 3\%, and 5\% vs. 1\% for the miltefosine and SSG groups, respectively). Initial treatment failure with miltefosine occurred in 18\% of HIV-coinfected patients, compared with treatment failure in 5\% of non-HIV-infected patients. At 6 months after treatment, 174 (60\%) of the 290 miltefosine recipients and 189 (65\%) of the 290 SSG recipients experienced cure; 30 (10\%) of 290 in the miltefosine group and 7 (2\%) of 290 in the SSG group experienced relapse, and the mortality rate was 6\% in the miltefosine group, compared with 12\% in the SSG group. HIV-infected patients had higher rates of relapse (16 [25\%] of 63 patients), compared with non-HIV-infected patients (5 [5\%] of 131). CONCLUSIONS: Treatment with miltefosine is equally effective as standard SSG treatment in non-HIV-infected men with VL. Among HIV-coinfected patients, miltefosine is safer but less effective than SSG. This article was published in Clin Infect Dis and referenced in Journal of Bacteriology & Parasitology

Relevant Expert PPTs

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords